Walkthrough · public protocol
We wanted to show Loom on a protocol anyone can check. SWOG S1505 is public, it’s a real cancer trial, and it’s demanding: two chemotherapy regimens, surgery in between, and follow-up over years. Here is the study, what it found, and what Loom did with its protocol.
The study
S1505 was a randomised phase 2 trial run by the SWOG Cancer Research Network with the US National Cancer Institute. It asked whether giving chemotherapy both before and after surgery could help people with pancreatic adenocarcinoma that can be removed by surgery. Patients were randomised to one of two regimens, mFOLFIRINOX (fluorouracil, irinotecan and oxaliplatin) or gemcitabine with nab-paclitaxel, given for 12 weeks before surgery and 12 weeks after. The primary outcome was overall survival at two years.[1][2]
To take part, patients needed a confirmed tissue diagnosis, a tumour judged resectable on imaging, and a performance status of 0 or 1. Its outcome measures are timed from more than one starting point: registration, the last dose of the third preoperative cycle, and surgery.[1][2]
What it found
147 patients enrolled at academic and community centres across the US, and 102 were eligible and evaluable. Two-year overall survival was 47% with mFOLFIRINOX and 48% with gemcitabine and nab-paclitaxel. Neither was significantly above the trial’s 40% threshold, so the trial did not show better survival than earlier trials of chemotherapy after surgery alone. It did show that chemotherapy around surgery was tolerable, with high rates of successful resection, and that strict resectability criteria were hard to apply: central radiology review found 43 of the enrolled patients (29%) had disease beyond them.[2]
Of the 77 eligible patients who went on to surgery, 73 had their tumour removed.[3]
[founder to approve the summary; a clinician’s read is advised before launch]
What Loom did
Loom read S1505’s protocol, [founder to confirm: the protocol document posted with the ClinicalTrials.gov record, and its version]. S1505 is one of the public protocols we hold out of Loom’s development: we test Loom on them and don’t tune it on them. [founder to confirm this still holds for the run the page shows]
From it, Loom drafted the study map: the objectives and endpoints, the eligibility criteria, and the visits and assessments, each item linked to the passage it came from.
Draft · from the protocol
Endpoint
Arms
[Placeholder. No eCRF run on S1505 is recorded yet. Once a run is recorded, write what Loom drafted, for example: “Once the map was approved, Loom drafted the forms and placed them at their visits, each question linked back to its passage.”]
Before registration
Every 28 days
4–8 weeks after Cycle 3
Not tied to a visit
Where the protocol’s own words didn’t settle something, Loom didn’t guess: it raised a question for the team and set the passages beside it. We count those flags as Loom doing its job. A good flag is a decision a person would have had to make anyway, found early and shown with its evidence.
[Placeholder: S1505’s flags from the run the page shows, each with its section and page, and how the team settled it.]
Visit · Needs a decision
After the evaluation report
We’ll publish Loom’s results on S1505 with the method behind them and the misses, once our held-out evaluation report is final. Until then, we’d rather show you the work than a number.
A question we keep asking
Every trial starts helping people only once its first participant enrols. How many more patients could be helped if every study reached that day sooner?
Sources